top of page


Pfizer licenses Starna Therapeutics' in vivo CAR-T programmes in deal worth up to $2.63 billion
Pfizer has secured rights to three preclinical in vivo CAR-T programmes from Starna Therapeutics through a licensing agreement featuring $330 million upfront and up to $2.3 billion in contingent milestone payments.

nuaxia
3 days ago2 min read


ArsenalBio cuts 99 jobs as it pivots to in vivo CAR-T development
ArsenalBio is cutting 99 jobs as it restructures the company around a strategic shift towards in vivo CAR-T development.

nuaxia
Sep 21 min read
bottom of page